Last edition
News about "AbbVie Secures Global Manufacturing "
AbbVie and RemeGen, a China-based innovative biopharmaceutical company, have entered into an exclusive licensing agreement covering the development, manufacturing, and commercialization of RC148, a novel investigational PD-1/VEGF-targeted bispecific antibody for the treatment of advanced solid tumours.
AbbVie Secures Global Manufacturing | 13/01/2026 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members